CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 155 enrolled
Drug / intervention
Osimertinib +1 moredrug
Likely dose
Osimertinib 80 mg orally once daily; Bevacizumab 15 mg/kg IV on day 1 of every 3-week cycle (in combination arm)AI-extracted
Key inclusion· 7
  • ✓Age >18 years
  • ✓Stage IIIb/IIIc (not amenable to radical therapy) or IVa/IVb NSCLC with prior progression on EGFR TKI (erlotinib, gefitinib, dacomitinib, or afatinib)
  • ✓Predominantly non-squamous NSCLC with pathological diagnosis
  • ✓Maximum one line of prior platinum-based chemotherapy
Key exclusion· 5
  • ✕Mixed NSCLC with predominantly squamous cell cancer or any small cell lung cancer component
  • ✕Symptomatic or active CNS metastases with progressive growth or increasing steroid requirement
  • ✕Concurrent potent CYP3A4 inducers (medications or herbal supplements)
  • ✕Unresolved toxicities from prior therapy >CTCAE v4.0 grade 1 (except alopecia and grade 2 platinum-related neuropathy)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03133546
NCT03133546Phase 2Completed
CompareCT.gov

A Randomised Phase II Trial of Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

ETOP IBCSG Partners Foundation·interventional·Posted Apr 28, 2017·Updated Feb 6, 2026

In Brief

A Phase 2 clinical trial evaluating Osimertinib and Bevacizumab for Non Small Cell Lung Cancer Metastatic. Completed, enrolled 155 participants across 25 sites in 6 countries.

Detailed Summary

BOOSTER is a randomised, controlled, phase II trial comparing osimertinib and bevacizumab versus osimertinib alone as second-line treatment in patients with stage IIIb-IVb non-small cell lung carcinoma (NSCLC) harbouring activating EGFR (exon 19 deletion or L858R) and T790M resistance mutation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer Metastatic
CountriesIreland, Netherlands, Singapore, South Korea, Spain, Switzerland
CollaboratorsAstraZeneca, Hoffmann-La Roche

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 28, 2017
Enrollment StartMay 31, 2017
Primary CompletionFeb 22, 2021
Study CompletionFeb 29, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.2 years ago

Interventions

Osimertinibdrug

Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration. AstraZeneca will supply osimertinib as tablets for oral administration.

Bevacizumabdrug

Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.